Ki Y. Chung

Ki Y. Chung

Hematology | Hematology Oncology | Oncology

2400 Boiling Springs Rd
Boiling Springs, SC 29316

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.

Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.

Journal: JCO oncology advances

Published: April 29, 2026

Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Journal: Cancers

Published: January 08, 2026

Metabolic Signatures of Breast Cancer Subtypes and the Metabolic Impact of Chemotherapy.

Metabolic Signatures of Breast Cancer Subtypes and the Metabolic Impact of Chemotherapy.

Journal: Metabolites

Published: October 29, 2025

First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors.

First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors.

Journal: British journal of cancer

Published: October 15, 2024

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.

Journal: BJC reports

Published: August 15, 2024

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Journal: Nature medicine

Published: April 24, 2024

Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.

Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 04, 2024

Effects of Origanum majorana on Breast Cancer Cells: An Alternative to Chemotherapy?

Effects of Origanum majorana on Breast Cancer Cells: An Alternative to Chemotherapy?

Journal: Metabolites

Published: September 09, 2023

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.

Journal: Investigational new drugs

Published: May 06, 2022

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 20, 2022

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 21, 2021

A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers.

A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers.

Journal: The oncologist

Published: March 05, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026